Found: 6
Select item for more details and to access through your institution.
Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.1065130
- By:
- Publication type:
- Article
Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 9, p. 1, doi. 10.1111/cts.70021
- By:
- Publication type:
- Article
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01334-z
- By:
- Publication type:
- Article